Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice

BACKGROUND: Inconsistency of real-world medication use with labeled indications may affect cost and clinical value of pharmacotherapy. PCSK-9 inhibitors are labeled in the US for use with statins to reduce low-density lipoprotein cholesterol in patients with atherosclerotic cardiovascular disease (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Fairman, Kathleen A, Davis, Lindsay E, Sclar, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548274/
https://www.ncbi.nlm.nih.gov/pubmed/28831261
http://dx.doi.org/10.2147/TCRM.S143008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548274/
https://www.ncbi.nlm.nih.gov/pubmed/28831261
http://dx.doi.org/10.2147/TCRM.S143008

Ejemplares similares